Materialise NV
NASDAQ•MTLS
CEO: Ms. Brigitte de Vet-Veithen
セクター: Technology
業種: Software - Application
上場日: 2014-06-25
Materialise NV provides additive manufacturing and medical software, and 3D printing services in the Americas, Europe and Africa, and the Asia-Pacific. The company operates through three segments: Materialise Software, Materialise Medical, and Materialise Manufacturing. The Materialise Software segment offers software through programs and platforms that enable and enhance the functionality of 3D printers and of 3D printing operations. Its software interfaces between various types of 3D printers; and various software applications and capturing technologies, including computer-aided design/computer-aided manufacturing packages and 3D scanners. This segment serves 3D printing machine manufacturers; production companies and contract manufacturers in automotive, aerospace, consumer goods, and hearing aid industries; and 3D printing service bureaus through its sales force, Website, and third party distributors. The Materialise Medical segment provides medical software that allows medical-image based analysis, planning, and engineering, as well as patient-specific design and printing of surgical devices and implants. It serves medical device companies, hospitals, universities, research institutes, and industrial companies through its direct sales force, Website, and picture archiving and communication system. The Materialise Manufacturing segment provides 3D printing services, design and engineering services, and rapid prototyping and additive manufacturing of production parts to industrial and commercial customers. The company has collaboration agreements with Zimmer Biomet Holdings, Inc.; Encore Medical, L.P.; DePuy Synthes Companies of Johnson & Johnson; Limacorporate Spa; Mathys AG; Corin Ltd; Smith & Nephew Inc.; Corin Ltd; Medtronic Inc.; and Abbott Laboratories Inc. Materialise NV was incorporated in 1990 and is headquartered in Leuven, Belgium.
連絡先情報
時価総額
$311.28M
PER (TTM)
33.5
66.7
配当利回り
--
52週高値
$6.80
52週安値
$3.93
52週レンジ
順位50Top 68.9%
3.1
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
弱い • 3.1 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025
財務ダッシュボード
Q4 2025 データ
売上高
$80.90M+0.00%
直近4四半期の推移
EPS
$0.11+0.00%
直近4四半期の推移
フリーCF
$1.23M+0.00%
直近4四半期の推移
2024 Annual 決算ハイライト
主なハイライト
Total Revenue Increased 4.2% Total revenue reached €266.8M in 2024, marking a 4.2% increase over €256.1M reported in 2023.
Medical Segment Revenue Strong Materialise Medical revenue grew 14.8% to €116.4M in 2024, driven by device and service sales growth across channels.
Net Profit Doubled in 2024 Net profit reached €13.4M in 2024, showing substantial improvement, up 100.3% compared to €6.7M profit in 2023.
FEops AI Acquisition Completed Acquired FEops NV in July 2024 for K€2,985 consideration to expand AI-driven simulation capabilities in heart care.
リスク要因
Internal Controls Found Ineffective Material weaknesses identified in risk assessment and monitoring processes resulted in management concluding controls were ineffective.
Geopolitical Instability Impacts Kyiv Operations in Kyiv office remain subject to continuous reorganization, uncertainty, and instability due to ongoing armed conflict.
Competition Threatens Market Standard Failure to maintain or increase market share or reputation risks software and product standing becoming obsolete against competitors.
Medical Regulatory Compliance Costly Medical segment faces substantial costs and risks managing complex, evolving regulations like FDA clearance and ISO 13485 compliance.
見通し
Accelerating Cloud Software Transition Strategy focuses on strengthening horizontal platforms and accelerating migration to cloud-based SaaS models, despite near-term revenue volatility.
Investing in Vertical Applications Growth strategy centers on developing specialized vertical applications, like personalized medical devices and wearables initiatives.
Addressing ESG Reporting Requirements Preparing for mandatory sustainability reporting under CSRD starting 2025/2027, requiring inside-out and outside-in materiality assessments.
Integrating FEops AI Technology Expect acquisition of FEops to expand cardiovascular solutions by advancing predictive simulation capabilities for personalized treatment.
同業比較
売上高 (TTM)
$3.85B
$2.69B
$421.54M
粗利益率 (最新四半期)
85.4%
81.0%
78.6%
主要指標
銘柄コード | 時価総額 | PER (TTM) | ROE (TTM) | 負債比率 |
|---|---|---|---|---|
| MITK | $688.35M | 42.9 | 6.9% | 35.2% |
| RXT | $589.49M | -2.6 | 19.6% | 17.3% |
| PUBM | $413.80M | -28.1 | -5.6% | 6.4% |
長期トレンド
直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
5.0%
安定成長
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
75%
キャッシュフローの変動が大きい
深度リサーチ
次回決算:2026年4月23日
EPS:-
|売上高:-
財務データ
決算説明会
財務レポート
ニュース
損益計算書
バランスシート
キャッシュフロー計算書
財務比率
変化率
損益計算書 | 直近12ヶ月 |
|---|
データなし